Journal of Substance Abuse Treatment
Volume 26, Issue 4 , Pages 285-294 , June 2004

Naltrexone for heroin dependence treatment in St. Petersburg, Russia

  • Evgeny M Krupitsky, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Edwin E Zvartau, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Dimitry V Masalov, M.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Marina V Tsoi, M.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Andrey M Burakov, M.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Valentina Y Egorova, M.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Tatyana Y Didenko, M.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Tatyana N Romanova, M.S.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Eva B Ivanova, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Anton Y Bespalov, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Elena V Verbitskaya, Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Nikolai G Neznanov, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Alexandr Y Grinenko, M.D., Ph.D.

      Affiliations

    • St. Petersburg Scientific Research Center of Addictions and Psychopharmacology, affiliated with St. Petersburg State Pavlov Medical University, Russia
    • ,
  • Charles P O'Brien, M.D.

      Affiliations

    • University of Pennsylvania, Department of Psychiatry and Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA
    • ,
  • George E Woody, M.D.

      Affiliations

    • Corresponding Author InformationCorresponding author. University of Pennsylvania, Department of Psychiatry and Veterans Affairs Medical Center; Treatment Research Institute, 600 Public Ledger Building, 150 S. Independence Mall (W) Philadelphia, PA 19106, USA
    • University of Pennsylvania, Department of Psychiatry and Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA

Received 13 July 2003 ,Revised 4 December 2003 ,Accepted 5 February 2004.

References 

  1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed.. Washington, DC: Author; 1994;
  2. Anton RF, Hogan I. Multiple family therapy and naltrexone in the treatment of opiate dependence. Drug and Alcohol Dependence. 1981;8:157–168
  3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry. 1961;4:561–571
  4. Callahan EJ, Rawson RA, McCleave B, Arias R, Glazer M, Liberman RP. The treatment of heroin addiction: Naltrexone alone and with behavior therapy. International Journal of the Addictions. 1980;15(6):795–807
  5. Carroll KM, Ball SA, Nick C, O'Connor PG, Egan DA, Frankforter TL, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence–efficacy of contingency management and significant other involvement. Archives of General Psychiatry. 2001;58(8):755–761
  6. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. Journal of Substance Abuse Treatment. 1997;14(6):529–534
  7. Grabowski J. Effects of contingent payment on compliance with a naltrexone regimen. American Journal of Drug and Alcohol Abuse. 1979;6:355–365
  8. Judson BA, Carney TM, Goldstein A. Naltrexone treatment of heroin addiction: Efficacy and safety in a double blind dosage comparison. Drug and Alcohol Dependence. 1981;7:325–346
  9. Kleber HD, Kosten TR. Naltrexone induction: Psychologic and pharmacologic strategies. Journal of Clinical Psychiatry. 1984;45:29–38
  10. Kleber H, Kosten T, Gaspari J. Nontolerance to opioid antagonism of naltrexone. Biological Psychiatry. 1985;20:66–72
  11. Krupitsky EM, Burakov AM, Romanova TN, Vostrikov VV, Grinenko AY. The syndrome of anhedonia in recently detoxified heroin addicts: assessment and treatment. In: Abstracts of the International Meeting “Building International Research on Drug Abuse: Global Focus on Youth”. Scottsdale, AZ: National Institute on Drug Abuse; 1998;p. 15
  12. Krupitsky EM, Masalov DV, Didenko TY, Burakov AM, Romanova TN, Zvartau EE, et al. Prevention of suicide by naltrexone in a recently detoxified heroin addict. European Addiction Research. 2001;7:87–88
  13. Krupitsky EM, Burakov AM, Romanova TN, Dunaevsky IV, Strassman R, Grinenko AY. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment. 2002;23:273–283
  14. Krupitsky EM, Zvartau EE, Lioznov DA, Tsoy MV, Belyaeva TV, Antonova TV, et al. Prevalence of alcoholism and addictions among patients with infectious diseases in St. Petersburg, Russia. In: Abstract from meeting of College on Problems of Drug Dependence. 2003;p. 89; Bal Harbor, FL
  15. McLellan AT, Luborsky L, Cacciola J, Griffith J. New data from the Addiction Severity Index: Reliability and validity in three centers. Journal of Nervous and Mental Disease. 1985;173:412–423
  16. Mercer D, Woody GE. The Penn-VA Addiction Counseling Manual. 1998; Available on NIDA web site
  17. Meyer RE, Mirin SM, Zackow F. Community outcome on narcotic antagonists. In:  Meyer RE,  Mirin SM editor. The heroin stimulus. New York: Plenum Press; 1979;
  18. Monitoring the Future. Trends in Lifetime Prevalence of use of Various Drugs for Eight, Tenth and Twelfth Graders. 1991–2000. Ann Arbor, MI: University of Michigan Press; 2000;
  19. Navaline HA, Snider EC, Petro C, Tobin D, Metzger D, Alterman A, et al. Preparations for AIDS vaccine trials. An automated version for the Risk Assessment Battery (RAB): Enhancing the assessment of risk behaviors. AIDS Research and Human Retroviruses. 1994;10:281–283
  20. Nunes EV, Quitkin FM, Donovan SJ, Deliyannides D, Ocepec-Welikson K, Koenig T, et al. Imipramine treatment of opiate dependent patients with depressive disorders. Archives of General Psychiatry. 1998;55:153–160
  21. O'Brien CP, Greenstein R, Mintz J, Woody GE. Clinical experience with naltrexone. American Journal of Drug and Alcohol Abuse. 1975;2:365–377
  22. O'Brien CP, Childress AR, McLellan AT, Ternes JM, Ehrman R. Use of naltrexone to extinguish opioid conditioned responses. Journal of Clinical Psychiatry. 1984;45:53–56
  23. O'Malley SS, Jaffe A, Chang G, Schottenfeld RS, Meyer RE, Rounsaville BJ. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Archives of General Psychiatry. 1992;49:881–887
  24. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  25. Resnick R, Schuyten-Resnick E, Washton AM. Narcotic antagonists in the treatment of opioid dependence: review and commentary. Comprehensive Psychiatry. 1979;20:116–125
  26. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction?. In:  Onken LS,  Blaine JD,  Boren JJ editor. Integrating behavioral therapies with medications in the treatment of drug dependence. Rockville, MD: National Institutes of Health; 1995; NIDA Research Monograph, Vol. 150, NIH Publication No. 95-3899, pp. 37–52
  27. Sideroff SI, Charuvastra VC, Jarvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. American Journal of Drug and Alcohol Abuse. 1978;5:415–423
  28. Spielberger CD, Anton WD, Bedell J. In:  Zuckerman M,  Spielberger CD editor. The nature and treatment of test anxiety. Emotion and Anxiety: New concepts, methods and applications. Hillsdale, NJ: Erlbaum; 1976;
  29. Tennant FS, Rawson RA, Cohen AI, Mann A. Clinical experience with naltrexone in suburban opioid addicts. Journal of Clinical Psychiatry. 1984;45:42–45
  30. Washton AM, Pottash AC, Gold MS. Naltrexone in addicted business executives and physicians. Journal of Clinical Psychiatry. 1984;45:39–41

PII: S0740-5472(04)00007-8

doi: 10.1016/j.jsat.2004.02.002

Journal of Substance Abuse Treatment
Volume 26, Issue 4 , Pages 285-294 , June 2004

Article Tools

* Image Usage & Resolution